Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

3 Humongous Healthcare Stocks This Week 4-4-14


Published on

The biggest winners in all of healthcare over the last week

  • Be the first to comment

  • Be the first to like this

3 Humongous Healthcare Stocks This Week 4-4-14

  1. 1. 3 Humongous Health-Care Stocks This Week
  2. 2. The old adage says that April showers bring May flowers. However, at least three health-care stocks blossomed big-time in the first few weeks of April. Here are your most humongous health-care winners over the past week. Source: Wikimedia Commons
  3. 3. Shares of the biotech skyrocketed 42% this week. MannKind Corporation (Nasdaq: MNKD) Source: Yahoo! Finance
  4. 4. • An FDA advisory committee recommended approval of Afrezza. • The vote for recommending approval for the inhaled insulin in treating type 1 diabetes was 13- 1, while the vote on type 2 diabetes was 14-0. • The FDA is scheduled to make its decision by April 15. Why MannKind took a giant leap
  5. 5. Shares of the molecular diagnostics company jumped nearly 25% this week. Myriad Genetics (Nasdaq: MYGN) Source: Yahoo! Finance
  6. 6. • Medicare reimbursements for genetic breast cancer tests were upped 52% above earlier proposed pricing. • Myriad’s BRACAnalysis test is a direct beneficiary of the government’s surprising change. • Japanese financial firm Mizuhu quickly upgraded Myriad’s stock from a “neutral” rating to “buy.” Why Myriad Genetics moved ginormously
  7. 7. Shares of the robotic surgical systems maker climbed 18% higher for the week. Intuitive Surgical (Nasdaq: ISRG) Source: Yahoo! Finance
  8. 8. • The FDA cleared Intuitive’s new da Vinci Xi surgical system. • The new system should greatly expand the types of surgeries that can be performed. • Investment firm William Blair raised its estimate of the potential market size for Intuitive’s products by 44% in response to the FDA decision. Why Intuitive Surgical surged
  9. 9. • While Myriad Genetics and Intuitive Surgical could do very well in 2014, my pick from this week’s best health-care stocks is MannKind. • It’s been a long time coming, but MannKind appears to now have a great shot at gaining FDA approval for Afrezza. • If the biotech lines up a solid partner to market the inhaled insulin, this stock could be one of the biggest winners of the year. • Downside risks remain -- the FDA might not grant approval; a partner might not be found; Afrezza might not take off as the company hopes. • Overall, though, MannKind’s chances of sustained success seem pretty good. Best pick to stay humongous?
  10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!